REGENXBIO to Present at Key Healthcare and Ophthalmology Conferences
Event summary
- REGENXBIO will participate in the 2026 RBC Capital Markets Global Healthcare Conference on May 20 and the Stifel 2026 Virtual Ophthalmology Forum on May 26.
- Both events feature fireside chats with REGENXBIO leadership.
- Live webcasts will be available on REGENXBIO's website, with replays accessible for 30 days post-event.
- REGENXBIO's pipeline includes late-stage gene therapies for rare and retinal diseases, including RGX-202 for Duchenne and RGX-121 for MPS II.
The big picture
REGENXBIO's participation in these conferences comes as the gene therapy sector faces increasing scrutiny over clinical trial outcomes and commercial viability. The company's focus on rare and retinal diseases positions it in a niche but growing market, with partnerships playing a critical role in its strategic roadmap. Investors will be watching for updates on key pipeline candidates and the potential for near-term milestones.
What we're watching
- Pipeline Progress
- How REGENXBIO's updates on RGX-202 and RGX-121 will impact investor confidence in its late-stage pipeline.
- Strategic Partnerships
- Whether collaborations with AbbVie and Nippon Shinyaku will accelerate regulatory approvals or commercialization timelines.
- Market Positioning
- The pace at which REGENXBIO can differentiate itself in the competitive gene therapy space.
Related topics